SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently the center of intense debate following a record-revenue earnings report that was overshadowed by investor disappointment regarding the narrowing window for its Neutron rocket debut. The community is sharply divided, with bulls highlighting the massive contract backlog and long-term potential of the GHOST launch system, while bears focus on the delay risks and high valuation metrics.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors weigh strong operational fundamentals and record-high European natural gas spreads against ongoing geopolitical volatility in the Strait of Hormuz. Community sentiment is sharply divided, with bulls pointing to the company's massive revenue backlog and upcoming earnings catalyst, while others debate the impact of broader energy sector manipulation and persistent Middle East instability on the stock's price.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is experiencing heightened volatility and intense community debate as investors react to stalled legislative progress and concerns over potential downside pressure. While some proponents continue to advocate for long-term accumulation based on fundamental utility, a vocal segment of the community is expressing frustration with recent price action and the ongoing lack of regulatory clarity.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

The SPDR Gold Shares ETF (GLD) is capturing significant trader attention as gold prices attempt a breakout, with community sentiment driven by a mix of speculative trading and macroeconomic anxiety over potential recession signals. Investors are closely monitoring labor market data and ongoing geopolitical developments, which are fueling active debates about gold's role as a hedge against currency debasement and a tool for navigating market volatility.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea Ltd is capturing investor attention following its recent quarterly report, which featured strong revenue growth and improved Shopee marketplace performance, despite a slight earnings miss. While some community members are concerned by recent insider selling, bullish investors remain focused on the company's long-term potential in the Southeast Asian e-commerce and fintech sectors, often comparing its growth trajectory to major global platforms.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is currently seeing significant community interest following recent Phase 3 clinical data, with investors actively debating the long-term commercial potential of its pipeline versus the competitive landscape. While participants are focused on the clinical results and the company's financing flexibility, the conversation remains driven by speculation regarding potential buyout interest and the strategic timing of upcoming data disclosures.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

The iShares Silver Trust (SLV) is seeing heightened investor interest as silver and gold experience a potential rotation, driven by broader market uncertainty and speculation around macroeconomic catalysts like interest rate policy. Community sentiment is deeply divided, with many traders actively discussing a 'squeezed' setup that could trigger a significant breakout, while others urge caution and warn of potential volatility ahead.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending as investors aggressively position ahead of upcoming earnings, fueled by massive institutional buying and excitement over its role in the critical AI infrastructure buildout. The community is actively debating the stock's massive backlog and debt profile, with many traders looking for confirmation that the company's aggressive infrastructure expansion will translate into sustainable margin growth.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is currently generating intense community debate as retail traders weigh a recent earnings loss and margin compression against strong revenue growth and aggressive buyback commitments. While some investors fear regulatory headwinds and competitive pressures, the bullish camp remains focused on the company's long-term expansion into peptides and AI-driven health services as catalysts for future profitability.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork is seeing heightened investor attention driven by strong earnings results, consistent beats on quarterly estimates, and active share repurchase programs that underscore management's confidence. The community remains divided between long-term bulls highlighting the company's valuation and AI integration potential, and skeptics who argue that AI-driven automation may continue to displace demand for traditional freelance services.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why You Should Add INKT Stock to Your Portfolio Now

MiNK advances agenT-797 across respiratory, oncology and immune disease studies while expanding its next-generation engineered iNKT pipeline.

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company PR Newswire SAN FRANCISCO, June 2, 2026 Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)SAN FRANCISCO, June 2...

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the first disclosure of Phase 2 data from the C-800-23 study evaluating botensilimab (BOT), Agenus multifunctional Fc-enhanced anti-CTLA-4 antibody, with balstilimab (BAL), an anti-PD-1 antibody, in patients with...

Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new retrospective data showing that Noetiks artificial intelligence-based TARIO-2 model identified spatial tumor microenvironment patterns associated with clinical outcomes from routine pretreatment tumor pathology...

Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of Phase 1b data evaluating botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody, in combination...

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the first quarter ended March 31, 2026, and provided an operational update on botensilimab...

MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Consensus Recommendation of "Hold" by Analysts

MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) has received an average rating of "Hold" from the five analysts that are presently covering the company, Marketbeat.com reports. One analyst...

Short Interest in MiNK Therapeutics, Inc. (NASDAQ:INKT) Drops By 30.6%

MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totaling 96,493 shares, a...

MiNK Therapeutics (NASDAQ:INKT) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded shares of MiNK Therapeutics to a "sell" rating in a research note on Saturday...

MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Recommendation of "Hold" by Brokerages

MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) has received a consensus rating of "Hold" from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a b...

$INKT Q1 '26 Earnings Results & Recap

MiNK Therapeutics ended Q1 2026 with $9.5M in cash and cash equivalents. The net loss for MiNK Therapeutics was approximately $2.7M, or $0.57 per share, in Q1 2026.

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded by Garo H. Armen in 2017 and is headquartered in New York, NY.

MiNK Therapeutics Inc

Why Did INKT Stock Jump 30% Today?

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.60	--	--	N/A
Q1 '26	-$0.77	-$0.57	25.97%	BEAT
Q4 '25	-$0.68	-$0.52	23.53%	BEAT
Q3 '25	-$0.86	-$0.65	23.98%	BEAT
Q2 '25	-$0.55	-$1.06	-93.90%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings